Companies developing tests for cancer therapy selection, therapy monitoring, and screening received most of the private investment, funding experts said.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
Following its IPO in September, the company is expanding its presence with increased product offerings in the pipeline and a renewed focus on reimbursement and R&D.
The German company offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs.
Anpac currently offers a test in China for detecting the risk of 26 cancer types using the firm's so-called cancer differentiation analysis technology.
The German company offers rare disease genetic tests and services for clinical applications and to support clients' drug discovery and development programs.
Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs.
Exagen, which develops and markets autoimmune tests, went public on the Nasdaq today and expects gross proceeds of $50.4 million from its IPO.
The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.
The company markets genetic tests for skin cancer including DecisionDx-Melanoma for identifying high-risk stage I and II cutaneous melanoma patients.